長江雲客户端

長江雲公眾號

外交部:中國已有5支疫苗正在多國開展III期臨牀試驗

截至目前,中國已有5支疫苗正在阿聯酋、巴西、巴基斯坦、祕魯等多國開展III期臨牀試驗。

2020年11月18日,外交部發言人趙立堅主持例行記者會,有記者問:近期,多國企業新冠肺炎疫苗研發取得了新的進展。我們知道,中國有幾家企業的疫苗也在多國開展臨牀試驗,你可否介紹更多情況?中方參與疫苗國際合作進展如何?

Q: Vaccine R&D companies in multiple countries have achieved new progress in COVID-19 vaccine development. We know some Chinese vaccine candidates are under clinical trials in many countries. Can you give us more details on that? And how is China's participation in global vaccine cooperation going?

趙立堅:感謝你對中國相關企業疫苗研發進展的關注。疫苗是抵禦新冠病毒的有力武器。中國疫苗研發進展可以用兩個“五”來概括:

Zhao Lijian: Thank you for your attention on Chinese vaccine R&D. Vaccines are powerful weapons against the coronavirus. China's vaccine development progress can be summed up in two "fives" :

第一個“五”,新冠肺炎疫情發生以來,中國政府第一時間佈局了滅活疫苗、重組蛋白疫苗、腺病毒載體疫苗、減毒流感病毒載體疫苗和核酸疫苗五條技術路線,規範有序開展研發工作。第二個“五”,中國已有5支疫苗正在阿聯酋、巴西、巴基斯坦、祕魯等多國開展III期臨牀試驗,另有多支疫苗正在加緊推進I、II期臨牀試驗。

First, after the pandemic broke out, the Chinese government at the earliest time possible laid out five technical routes including inactivated vaccines, recombinant vaccines, adenovirus-based vaccines, live-attenuated vaccines and nucleic acid vaccines. Vaccine research and development has been carried out in an orderly manner. Second, five Chinese vaccine candidates are under clinical trials in countries including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.

中國疫苗研發單位和廣大科研工作者嚴格依據科學規律和監管要求,夜以繼日、全力以赴推進疫苗研發,為此付出艱辛努力。我和大家一樣都期待着能夠儘早聽到他們的好消息。

Following scientific rules and regulations, Chinese researchers and scientists have been working around the clock and making arduous efforts on the vaccines. Like you all, I look forward to hearing good news about them as soon as possible.

關於疫苗國際合作,中國政府和企業一直積極通過多雙邊渠道參與疫苗國際合作。除了剛才提到的同有關國家合作開展疫苗研發外,中方也同世界衞生組織、全球疫苗免疫聯盟、流行病防範創新聯盟等國際組織保持密切溝通與合作,加入了世衞組織“全球合作加速開發、生產、公平獲取新冠肺炎防控新工具”倡議和“團結計劃”國際多中心臨牀試驗。中方還加入了“新冠疫苗實施計劃”,以促進疫苗公平分配,確保為發展中國家提供疫苗,同時帶動更多有能力的國家支持“實施計劃”。中方期待中國疫苗研發完成後能夠儘早被納入“實施計劃”採購清單,為實現疫苗在發展中國家的可及性和可負擔性做出自己的貢獻。

The Chinese government and companies have been proactively participating in international cooperation on vaccines through bilateral and multilateral channels. Besides cooperation with the countries I talked about earlier, China is also in close communication and cooperation with international organizations such as the WHO, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations. We are part of the WHO-sponsored Access to COVID-19 Tools (ACT) Accelerator initiative and the Solidarity Trial for COVID-19 treatments. China has also joined COVAX to promote fair distribution of vaccines, ensure the provision of vaccines for developing countries, and encourage more capable countries to support COVAX. We hope Chinese vaccines will be included in COVAX's procurement list as soon as possible after their development, which will contribute to the accessibility and affordability of vaccines in developing countries.

關於疫苗國際合作,中國政府和企業一直積極通過多雙邊渠道參與疫苗國際合作。除了剛才提到的同有關國家合作開展疫苗研發外,中方也同世界衞生組織、全球疫苗免疫聯盟、流行病防範創新聯盟等國際組織保持密切溝通與合作,加入了世衞組織“全球合作加速開發、生產、公平獲取新冠肺炎防控新工具”倡議和“團結計劃”國際多中心臨牀試驗。中方還加入了“新冠疫苗實施計劃”,以促進疫苗公平分配,確保為發展中國家提供疫苗。同時帶動更多有能力的國家支持“實施計劃”。中方期待中國疫苗研發完成後能夠儘早被納入“實施計劃”採購的清單,為實現疫苗在發展中國家的可及性和可負擔性作出中國貢獻。

來源:外交部、外交部發言人辦公室、環球網

(責任編輯 何潛彬)

違法和不良信息舉報電話

鄂公網安備 42010602000216號